JOHNSON & JOHNSONの売上高は？

JOHNSON & JOHNSONの2025年度の売上高は$94.2Bです（前年比+6.0%）。

JOHNSON & JOHNSONの純利益は？

JOHNSON & JOHNSONの2025年度の純利益は$26.8Bです（前年比+90.6%）。

JOHNSON & JOHNSONのROEは？

JOHNSON & JOHNSONの2025年度のROE（自己資本利益率）は32.9%です。

企業一覧に戻る

JOHNSON & JOHNSON（JNJ）の決算・業績分析

JOHNSON & JOHNSONの2025年有価証券報告書をAI分析。売上高$94.2B(+6.0%)。Health Care。

SUMMARY — 業績サマリー

JOHNSON & JOHNSONの2025年度業績サマリー

JOHNSON & JOHNSON（証券コード: JNJ）の2025年度決算・業績分析。売上高は$94.2B（前年比+6.0%）。純利益は$26.8B（前年比+90.6%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。

JOHNSON & JOHNSONの2024年度注目ポイント

※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。

Net income declined by 14.1% YoY to $17.9B (XBRL), despite revenue growth of 1.6% to $80.0B (XBRL).
Free cash flow (FCF) reached $17.2B (XBRL), driven by $21.2B operating cash flow (OCF) and $4.0B CapEx (XBRL).
Net debt stood at $4.0B (0.1x EBITDA) (XBRL), reflecting strong liquidity despite $25.9B long-term debt (XBRL).
ROE of 24.2% (XBRL) and ROIC of 18.9% (XBRL) highlight strong returns for shareholders.

JOHNSON & JOHNSONの売上高変化の要因

•FY2024 revenue grew 1.6% YoY to $80.0B (XBRL), but 5-year CAGR remains modest at 0.9% (XBRL). Historical data shows volatility, with revenue declining from $82.6B (FY2022) to $78.7B (FY2023) before rebounding to $80.0B (FY2024). No segment-specific revenue data is available (N/A).

JOHNSON & JOHNSONの営業利益変化の要因

•Gross margin of 69.2% (XBRL) and operating margin of 43.9% (XBRL) reflect strong cost control. However, net income fell 14.1% YoY to $17.9B (XBRL), down from $20.9B in FY2023 (XBRL). Net margin of 22.4% (XBRL) remains robust despite the decline.

JOHNSON & JOHNSONの事業リスクと対応

Competitive pressures from generic/biosimilar products and cost-effective rivals may reduce earnings (10-K).

Manufacturing disruptions from supply chain issues, natural disasters, or quality deviations could cause product shortages (10-K).

Reliance on third-party manufacturers risks delays, increased costs, and regulatory compliance failures (10-K).

Loss of patent exclusivity for Innovative Medicine products may lead to generic competition and sales declines (10-K).

Failure to innovate with new products or technologies could harm competitiveness (10-K).

JOHNSON & JOHNSONの今後の見通し・業績予想

Management guidance and forward-looking trends are not explicitly detailed in the provided data (N/A).

JOHNSON & JOHNSONの事業内容

Johnson & Johnson operates in the healthcare sector, generating revenue through prescription medicines (e.g., REMICADE, SIMPONI) and medical devices (10-K). Key segments include Innovative Medicine (therapeutic areas like Immunology, Oncology) and MedTech (10-K). The company serves retailers, wholesalers, distributors, hospitals, and healthcare professionals, with no significant customer concentration (10-K). Competitive risks include generic/biosimilar products and third-party manufacturing dependencies (10-K).

JOHNSON & JOHNSONのAI業績分析レポート（2024年度）

Johnson & Johnson (JNJ) FY2024 Annual Report Analysis

Highlights

•Net income declined by 14.1% YoY to $17.9B (XBRL), despite revenue growth of 1.6% to $80.0B (XBRL).

•Free cash flow (FCF) reached $17.2B (XBRL), driven by $21.2B operating cash flow (OCF) and $4.0B CapEx (XBRL).

•Net debt stood at $4.0B (0.1x EBITDA) (XBRL), reflecting strong liquidity despite $25.9B long-term debt (XBRL).

•ROE of 24.2% (XBRL) and ROIC of 18.9% (XBRL) highlight strong returns for shareholders.

Business Overview

Revenue Analysis

FY2024 revenue grew 1.6% YoY to $80.0B (XBRL), but 5-year CAGR remains modest at 0.9% (XBRL). Historical data shows volatility, with revenue declining from $82.6B (FY2022) to $78.7B (FY2023) before rebounding to $80.0B (FY2024). No segment-specific revenue data is available (N/A).

Profitability Analysis

Gross margin of 69.2% (XBRL) and operating margin of 43.9% (XBRL) reflect strong cost control. However, net income fell 14.1% YoY to $17.9B (XBRL), down from $20.9B in FY2023 (XBRL). Net margin of 22.4% (XBRL) remains robust despite the decline.

Balance Sheet Analysis

Equity ratio of 44.2% (XBRL) and debt-to-equity (D/E) ratio of 1.33x (XBRL) indicate balanced leverage. Total assets decreased to $167.6B (XBRL) in FY2024 from $187.4B (XBRL) in FY2023, while total equity rose to $74.0B (XBRL) from $63.3B (XBRL). Net debt of $4.0B (XBRL) is 0.1x EBITDA (XBRL).

Cash Flow Analysis

Operating cash flow (OCF) totaled $21.2B (XBRL), with $17.2B FCF after $4.0B CapEx (XBRL). Dividends paid $11.7B (XBRL) and share repurchases reached $6.0B (XBRL). Capital expenditures (CapEx) intensity of 5.0% (XBRL) reflects disciplined investment.

Working Capital Analysis

Cash conversion cycle (CCC) of 91 days (XBRL) includes 68 days receivables, 166 days inventory, and 143 days payables (XBRL).

Risks

1.Competitive pressures from generic/biosimilar products and cost-effective rivals may reduce earnings (10-K).

2.Manufacturing disruptions from supply chain issues, natural disasters, or quality deviations could cause product shortages (10-K).

3.Reliance on third-party manufacturers risks delays, increased costs, and regulatory compliance failures (10-K).

4.Loss of patent exclusivity for Innovative Medicine products may lead to generic competition and sales declines (10-K).

5.Failure to innovate with new products or technologies could harm competitiveness (10-K).

Outlook